Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: DIMITRAKOPOULOS
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
Autorzy: Tsavaris Nicolas, Kosmas Christos, Gennatas Kostas, Vadiaka Maria, Paliaros Platon, Dimitrakopoulos Antonis, Diamantis Theodoros, Tsipras Heraklis, Papastratis George
Źródło: Med. Sci. Monitor 2002: 8 (9) s.PI65-PI69, bibliogr. 33 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • onkologia
  • toksykologia
  • farmacja
  • gastroenterologia

    Typ dokumentu:
  • tytuł obcojęzyczny
  • praca kliniczna

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Background: We evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU. Material/Methods: Etoposide was administered at 3 different dose levels (DL), in 3 groups of patients (Total - 60); DL-I - etoposide 80 mg/mý, 45 min i.v. infusion, DL-II - etoposide 120 mg/mý, and DL-III - etoposide 180 mg/mý. In all three levels etoposide was followed by LV 100 mg/mý i.v., 1-hour infusion, and 5-FU 500 mg/mý i.v. bolus. Treatment was adminsitered until disease progression or unacceptable toxicity. Results: No patients responded at DL-I, while 2 patients at DL-II and 3 at DL-III had a partial response (PR) (P 0.1). Two patients had stable disease (SD) at DL-I, 8 at DL-II, and 9 at DL-III (P 0.01). More patients progressed at DL-I (n = 19) compared to DL-II (n - 10) and DL-III (n = 8) (p 0.0007). The time to progression was 17, 15, and 14 weeks, respectively, for DL-I, -II, and -III (P = 0.9). Median survival was 30, 30, and 32.5 weeks, respectively, for DL-I, -II, and -III (P = 0.27). Toxicity was mainly neutropenia, diarrhea and mucositis at all DLs, significantly more intense in DL-III. No difference was noticed in responses between DL-II and DL-III, but toxicity in DL-III was more severe. Conclusions: The combination of etoposide with LV+5-FU has limited activity when adminsitered after failure of weekly LV+5-FU in patients with ACC.

    stosując format: